Cristin-person-ID: 42474
Person

Øyvind Hjertner

  • Stilling:
    Førsteamanuensis
    ved Institutt for klinisk og molekylær medisin ved Norges teknisk-naturvitenskapelige universitet
  • Stilling:
    Overlege hematologi
    ved Medisinsk klinikk ved St. Olavs Hospital HF

Resultater Resultater

Risk of multiple myeloma and other malignancies among first- and second-degree relatives of patients with multiple myeloma: A population-based study.

Langseth, Øystein Olstad; Myklebust, Tor Åge; Johannessen, Tom Børge; Hjertner, Øyvind; Waage, Anders. 2022, European Journal of Haematology. HELSEMR, STOLAV, FHI, NTNUVitenskapelig artikkel

Patterns of previous and secondary malignancies in patients with multiple myeloma.

Langseth, Øystein Olstad; Myklebust, Tor Åge; Johannessen, Tom Børge; Hjertner, Øyvind; Waage, Anders. 2021, European Journal of Haematology. HELSEMR, STOLAV, FHI, NTNUVitenskapelig artikkel

Incidence and survival of multiple myeloma: a population-based study of 10 524 patients diagnosed 1982–2017.

Langseth, Øystein Olstad; Myklebust, Tor Åge; Johannessen, Tom Børge; Hjertner, Øyvind; Waage, Anders. 2020, British Journal of Haematology. HELSEMR, STOLAV, FHI, NTNUVitenskapelig artikkel

Multiple myeloma and associated malignancies, a study on Norwegian registry data.

Waage, Anders; Hjertner, Øyvind. 2018, NMSG-møte september. NTNUVitenskapelig foredrag

Salvage bortezomib-dexamethasone and high-dose melphalan (HDM) and autologous stem cell support (ASCT) in myeloma patients at first relapse after HDM with ASCT. A phase-2 trial.

Gimsing, Peter; Hjertner, Øyvind; Abildgaard, Niels; Andersen, Niels Frost; Gedde-Dahl, Tobias Jr.; Gregersen, Henrik Echternach; Klausen, Tobias Wirenfeldt; Mellqvist, Ulf-Henrik; Linder, Olle; Lindås, Roald mfl.. 2015, Bone Marrow Transplantation. SAHLGREN, HERLEVHOSP, OUH, AALBORGUH, SDU, HAUKELAND, NTNU, KU, OUS, OREBRO, SUS, STOLAV, RH, AARHUSSYKEVitenskapelig artikkel
1 - 5 av 53 | Neste | Siste »